The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses
The deposition of 4-kDa amyloid β peptide in the brain is a prominent feature of several human diseases. Such process is heterogeneous in terms of causative factors, biochemical phenotype, localization and clinical manifestations. Amyloid β accumulates in the neuropil or within the walls of cerebral...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | JOUR |
| Materias: | |
| Acceso en línea: | http://hdl.handle.net/20.500.12110/paper_03643190_v27_n11_p1387_Morelli |
| Aporte de: |
| id |
todo:paper_03643190_v27_n11_p1387_Morelli |
|---|---|
| record_format |
dspace |
| spelling |
todo:paper_03643190_v27_n11_p1387_Morelli2023-10-03T15:27:37Z The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses Morelli, L. Llovera, R. Ibendahl, S. Castaño, E.M. Alzheimer disease Amyloid β Brain proteases Cerebrovascular amyloidoses Neurodegeneration Therapy amyloid beta protein amyloid precursor protein oligomer Alzheimer disease amyloid neuropathy brain blood vessel cerebrovascular disease clinical feature dementia disease association genetic disorder human molecular weight neuropathology neuropil nonhuman phenotype priority journal protein degradation protein localization protein transport review stroke Alzheimer Disease Amyloid beta-Protein Amyloidosis Brain Endopeptidases Humans Hydrolysis The deposition of 4-kDa amyloid β peptide in the brain is a prominent feature of several human diseases. Such process is heterogeneous in terms of causative factors, biochemical phenotype, localization and clinical manifestations. Amyloid β accumulates in the neuropil or within the walls of cerebral vessels, and associates with dementia or stroke, both hereditary and sporadic. Amyloid β is normally released by cells as soluble monomeric-dimeric species yet, under pathological conditions, it self-aggregates as soluble oligomers or insoluble fibrils that may be toxic to neurons and vascular cells, Lowering amyloid β levels may be achieved by inhibiting its generation from the amyloid β-precursor protein or by promoting its clearence by transport or degradation. We will summarize recent findings on brain proteases capable of degrading amyloid β with a special focus on those enzymes for which there is genetic, transgenic or biochemical evidence suggesting that they may participate in the proteolysis of amyloid β in vivo. We will also put in perspective their possible utilization as therapeutic agents in amyloid β diseases. JOUR info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/2.5/ar http://hdl.handle.net/20.500.12110/paper_03643190_v27_n11_p1387_Morelli |
| institution |
Universidad de Buenos Aires |
| institution_str |
I-28 |
| repository_str |
R-134 |
| collection |
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) |
| topic |
Alzheimer disease Amyloid β Brain proteases Cerebrovascular amyloidoses Neurodegeneration Therapy amyloid beta protein amyloid precursor protein oligomer Alzheimer disease amyloid neuropathy brain blood vessel cerebrovascular disease clinical feature dementia disease association genetic disorder human molecular weight neuropathology neuropil nonhuman phenotype priority journal protein degradation protein localization protein transport review stroke Alzheimer Disease Amyloid beta-Protein Amyloidosis Brain Endopeptidases Humans Hydrolysis |
| spellingShingle |
Alzheimer disease Amyloid β Brain proteases Cerebrovascular amyloidoses Neurodegeneration Therapy amyloid beta protein amyloid precursor protein oligomer Alzheimer disease amyloid neuropathy brain blood vessel cerebrovascular disease clinical feature dementia disease association genetic disorder human molecular weight neuropathology neuropil nonhuman phenotype priority journal protein degradation protein localization protein transport review stroke Alzheimer Disease Amyloid beta-Protein Amyloidosis Brain Endopeptidases Humans Hydrolysis Morelli, L. Llovera, R. Ibendahl, S. Castaño, E.M. The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses |
| topic_facet |
Alzheimer disease Amyloid β Brain proteases Cerebrovascular amyloidoses Neurodegeneration Therapy amyloid beta protein amyloid precursor protein oligomer Alzheimer disease amyloid neuropathy brain blood vessel cerebrovascular disease clinical feature dementia disease association genetic disorder human molecular weight neuropathology neuropil nonhuman phenotype priority journal protein degradation protein localization protein transport review stroke Alzheimer Disease Amyloid beta-Protein Amyloidosis Brain Endopeptidases Humans Hydrolysis |
| description |
The deposition of 4-kDa amyloid β peptide in the brain is a prominent feature of several human diseases. Such process is heterogeneous in terms of causative factors, biochemical phenotype, localization and clinical manifestations. Amyloid β accumulates in the neuropil or within the walls of cerebral vessels, and associates with dementia or stroke, both hereditary and sporadic. Amyloid β is normally released by cells as soluble monomeric-dimeric species yet, under pathological conditions, it self-aggregates as soluble oligomers or insoluble fibrils that may be toxic to neurons and vascular cells, Lowering amyloid β levels may be achieved by inhibiting its generation from the amyloid β-precursor protein or by promoting its clearence by transport or degradation. We will summarize recent findings on brain proteases capable of degrading amyloid β with a special focus on those enzymes for which there is genetic, transgenic or biochemical evidence suggesting that they may participate in the proteolysis of amyloid β in vivo. We will also put in perspective their possible utilization as therapeutic agents in amyloid β diseases. |
| format |
JOUR |
| author |
Morelli, L. Llovera, R. Ibendahl, S. Castaño, E.M. |
| author_facet |
Morelli, L. Llovera, R. Ibendahl, S. Castaño, E.M. |
| author_sort |
Morelli, L. |
| title |
The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses |
| title_short |
The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses |
| title_full |
The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses |
| title_fullStr |
The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses |
| title_full_unstemmed |
The degradation of amyloid β as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses |
| title_sort |
degradation of amyloid β as a therapeutic strategy in alzheimer's disease and cerebrovascular amyloidoses |
| url |
http://hdl.handle.net/20.500.12110/paper_03643190_v27_n11_p1387_Morelli |
| work_keys_str_mv |
AT morellil thedegradationofamyloidbasatherapeuticstrategyinalzheimersdiseaseandcerebrovascularamyloidoses AT lloverar thedegradationofamyloidbasatherapeuticstrategyinalzheimersdiseaseandcerebrovascularamyloidoses AT ibendahls thedegradationofamyloidbasatherapeuticstrategyinalzheimersdiseaseandcerebrovascularamyloidoses AT castanoem thedegradationofamyloidbasatherapeuticstrategyinalzheimersdiseaseandcerebrovascularamyloidoses AT morellil degradationofamyloidbasatherapeuticstrategyinalzheimersdiseaseandcerebrovascularamyloidoses AT lloverar degradationofamyloidbasatherapeuticstrategyinalzheimersdiseaseandcerebrovascularamyloidoses AT ibendahls degradationofamyloidbasatherapeuticstrategyinalzheimersdiseaseandcerebrovascularamyloidoses AT castanoem degradationofamyloidbasatherapeuticstrategyinalzheimersdiseaseandcerebrovascularamyloidoses |
| _version_ |
1807317135891890176 |